Your browser doesn't support javascript.
loading
Catalase application in cancer therapy: Simultaneous focusing on hypoxia attenuation and macrophage reprogramming.
Najafi, Alireza; Keykhaee, Maryam; Khorramdelazad, Hossein; Karimi, Mohammad Yahya; Nejatbakhsh Samimi, Leila; Aghamohamadi, Nazanin; Karimi, Milad; Falak, Reza; Khoobi, Mehdi.
  • Najafi A; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Keykhaee M; Biomaterials Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
  • Khorramdelazad H; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Karimi MY; Razi drug research center, Iran University of Medical Science, Tehran, Iran.
  • Nejatbakhsh Samimi L; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Aghamohamadi N; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Karimi M; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Falak R; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: falak.r@iums.ac.ir.
  • Khoobi M; Biomaterials Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: m-khoobi@tums.ac.ir.
Biomed Pharmacother ; 153: 113483, 2022 Sep.
Article en En | MEDLINE | ID: mdl-36076502
ABSTRACT
The tumor microenvironment (TME), as an immunosuppressive milieu, has a critical role in tumor progression and increases resistance to the conventional treatments. Among the abundant immunosuppressive cells in the TME, tumor-associated macrophages (TAMs) could be a promising target for reprogramming and potentiating the local anti-tumor response. On the other hand, hypoxia is a major barrier in treating solid tumors, which aggravates the situation and alleviates the anti-tumor immune responses. Moreover, catalase and catalase-mimicking compounds can efficiently participate in the TAMs polarization and hypoxia attenuation in the TME. In this review, we will introduce a practical and novel approach which can simultaneously reduce hypoxia and polarize TAMs in the TME. Furthermore, catalase therapeutic effects in combination with cancer therapy methods will be fully discussed. This work aims to inspire readers to explore new avenues for designing and development of next-generation catalase-based formulations for cancer therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article